Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Reorganized Through A Planned ReverseMerger

Radient Is Being Reorganized Through a Planned Reverse Merger


Part 1...Posted on April 19, 2015

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112893006

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

April 20,2015

Someone posted this recently...

"If there were a merger plan in place since 2009, it would have happened by now. Nobody invests $$$ millions in a takeover and allows it to drag on for six years without seeing any return on the investment."

"And nobody invests $$$ millions buying RPC and then RXPC stock in a creeping takeover plan and then allows the share registration to get revoked "as part of a secret plan." That is not how rich people get richer. There is NO WAY a "private company" allows their money to evaporate like that. There is no way the Lenders or any Hedge Funds acquire RXPC stock and hold it through share registration revocation."


First and foremost before we go to Part Two of the Radient Reorganization Plan Through A Planned Reverse Merger
we must prove to some the facts and not weak arguments you understand..Lets take Shumate Industries a corporation that was financially in trouble with patents pending and technology that was wanted by an investor. Similar to the investment group Capital Venture International wanted for their investors(Provista Diagnostic Angel Investors). Provista was interested in Dr-70 for their Breast and lung cancer tests to compliment their BT Test and lung test.. From this example and to show some that there are investors that are willing to wait up to 5 ears for a return on their investment even when a corporation is revoked..Here is just one example.On October 27, 2008 this SC 13 D was filed by Tejas Associates Inc.



http://www.sec.gov/Archives/edgar/data/1085254/000095012908005305/0000950129-08-005305-index.htm

http://www.sec.gov/Archives/edgar/data/1085254/000095012908005305/h64622sc13d.htm

On October 15, 2008, the Issuer and Tejas Research, among others, entered into a transfer agreement (the “Agreement”) pursuant to which, among other things, the Issuer granted to Tejas Research warrants to acquire an aggregate of 2,443,269 shares of Common Stock (the “Warrants”) and sold, assigned and transferred certain assets for an aggregate purchase price of $3.5 million in cash. On October 15, 2008, following the consummation of the transactions contemplated by the Agreement, Tejas Research transferred the Warrants to Intervale Capital, LLC, a Delaware limited liability company (“ICLLC”), and the Issuer executed and delivered a Common Stock Purchase Warrant to ICLLC.

(1) Texas Associates, Inc., a Nevada corporation (“Tejas Associates”), and (2) Tejas Research & Engineering, L.P., a Texas limited partnership (“Tejas Research”), relating to the shares of common stock, par value $.001 per share (the “Common Stock”) of Shumate Industries, Inc., a Delaware corporation (the “Issuer”), in order to provide disclosure regarding Tejas Research’s transfer to Intervale Capital, LLC, a Delaware limited liability company (“ICLLC”), on October 15, 2008 of warrants to acquire an aggregate of 2,443,269 shares of Common Stock.

On October 27, 2008 the investment asset was transferred to Intervale Capital LLC. Here are the SEC filings

The principal business of ICLLC is that of an investment limited liability company.

http://www.sec.gov/Archives/edgar/data/1448495/000095012908005306/0000950129-08-005306-index.htm

http://www.sec.gov/Archives/edgar/data/1085254/000095012908005306/h64623sc13d.htm

Who is Intervale Capital LLC...

http://www.intervalecapital.com/investment-portfolio

What happened after this investment by Intervale and allowed another company to license the Shumate technology for an investment of over 3 million dollars in October 2008...Shumate in similarity to Radient Revoked their Stock on a voluntarily basis for a lack of Annual filings. The last filing by Shumate was
on March 31, 2009.The investors held on to their investment during the time of revocation..Shumate came out when they were reverse merged from a private company.

http://www.sec.gov/Archives/edgar/data/1085254/000114420409017537/0001144204-09-017537-index.htm

The last 10-Q followed on May 15, 2009

http://www.sec.gov/Archives/edgar/data/1085254/000114420409027194/0001144204-09-027194-index.htm

Shumate had changed their name to Hemiwedge which was a division at the time.

On September 2, 2011. The company voluntarily revoked their stock similar to Radient..Hemiwedge came out of the Revocation by a Reverse Merger. Similar to how radient will come out of their Voluntary Revocation..So to argue it has never been done from a Voluntary revocation or why investors invest Millions of Dollars for payback in the future is not a strong argument and not true.

http://www.sec.gov/Archives/edgar/data/1085254/999999999712008017/9999999997-12-008017-index.htm

http://www.sec.gov/Archives/edgar/data/1085254/999999999712008017/filename1.pdf

http://www.prnewswire.com/news-releases/shumate-industries-updates-investors-on-hemiwedger-cartridge-valve-growth-57271427.html

The same poster stated this recently as well...

"Mac did not "voluntarily revoke the stock in 2014" as part of some merger plan. The SEC gave Mac two choices: file the missing financials for 2012 and 2013 and 2014, or revoke the registration of your stock. Mac chose the latter -- and then he resigned and left the company."

The SEC giving Mac two choices is UN-documented and not true. The attorneys are aware of the time period it takes for a SEC revocation to take hold..If there was such a notice as stated above,it would have to be disclosed in an 8-K SEC filing, because the severity and damage it would cause all Radient stock holders. The reason Mac filed the Voluntary revocation and included it in a 8-K is the same very reason it was filed in an 8-K SEC filing on May 6, 2014..Correction from the post above..The annual financial were not due until the end of Radient's fiscal year ending December 31, 2014, so the "missing already prepared documents" would have been for 2012 and 2013..Two years is the maximum allowed by the SEC.

The same poster asked this question

"Why, again, did Mac get rid of Jade?"

The Provista Diagnostic angel investors and the lenders were not interested in a Chinese company that wasn't relevant to what they were interested in. The investors were interested in PDX,and Radient IP's pertaining to Cancer tests..Also, Not a major reason for the investors decision to spin off Jade was a concern of Mac and shareholders, and lenders was that Jade was not forthright on their financials which they refused to share audited documentation as well as share monies with radient they claimed to have made in China..

The poster also stated:

"Mac chose the latter -- and then he resigned and left the company."

That is not a true statement..mac resigned as CEO and Director along with Mike Christiansen, who was appointed asa director,and was the last director before the aussies were appointed. A corporation has to have a President and Secretary. Mac remained as President and Akio remained as Secretary. When the Radient Corporation is reinstated in Delaware, Mac or akio are authorized to reinstate the corporation..William is also president of AMDL Diagnostics Inc. and Akio is the Secretary. They are still with the company.

"The Truth about the CIT lawsuits."

We won they Lost.. Seeking 20 million in damages? CIT is a very valuable asset..

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Part 2

Radient Is Being Reorganized Through A Planned Reverse Merger

What is LC Sentinel and who owns it. It is a collaboration between Provista Diagnostics and Radient. We will discuss in Part Two why we will prove that Global Cancer Diagnostics is and has developed the LC Sentinel Lung Cancer Test from the use of Dr-70 and Provista Diagnostics patented antibodies and Biomarkers. We will be presenting the rest of our hypothesis tomorrow morning with facts and opinions.

http://www.biocentury.com/products/lc_sentinel

http://www.biocentury.com/weekinreview/clinicalresults/2010-11-01/lc-sentinel-diagnostic-data-321886

When and how did LC Sentinel originate..

Provista to go public with breast, lung cancer testing technology
Posted on Sat/31/December 2011

"Recently, Gartner sold Phoenix-based Provista Life Sciences LLC’s breast and lung cancer testing technologies to a new company called Provista Diagnostics Inc., which he intends to take public by the middle of next year".

The PR clearly states that William and PLS sold the Lung Cancer and Breast Cancer to Provista Diagnostics. The lung cancer test he sold did not include LC Sentinel. LC Sentinel was owned by Radient and Provista Diagnostics. William and PLS sold the Lung Cancer test he owned before the collaboration with Radient. Provista Diagnostics on the other hand, was in an exclusive 5 year agreement with radient to research, develop and commercialize Dr-70. Having the lung cancer test from the purchase of the lung cancer test from PLS and William and the license to continue to research, develop and commercialize Dr-70, Provista Diagnostics after all the trials and studies were completed, introduced the LC Sentinel that GCDX is currently selling.


Mr. Gartner founded Global Cancer Diagnostics Inc. to commercialize a blood test for lung cancer that detects the disease in Stages 1 and 2 when it can be treated with much higher survivability rates. Those efforts are coming to fruition with the planned introduction of the GCDX Lung Cancer Test. The test will be sold through physicians and directly to consumers in the 27 states that allow DTC diagnostics. The most remarkable features are the ROC Accuracy of the test at 97.2% and its price at $99, eliminating the need for insurance reimbursement in most cases. With 43,000,000 current smokers in the U.S. alone who should receive annual testing, the market size is staggering.

In 2003, Mr. Gartner formed what became Provista Life Sciences to commercialize a highly accurate blood test for breast cancer. That company was sold in 2011 and now operates as Provista Diagnostics Inc. That company is now working toward FDA approval of the blood test for breast cancer.

Apparently the Lung cancer Test that was sold by PLS to Provista Diagnostics Inc. was transferred to Global Cancer Diagnostics on a license basis or GCDX will be coming a wholly owned subsidiary or a Division of Provista Diagnostics in the near future.

https://www.linkedin.com/pub/william-gartner/78/904/31?trk=pub-pbmap


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112640973


Lets start with the introduction of LC Sentinel...Notice that the agreement was with AMDL Diagnostics Inc..It was first validated for Breast Cancer detection using PLS BT Test now owned by Provista Diagnostics and Radient's Dr-70 technology. Later the Lung cancer detection was also introduced..This proves that Provista's Breast Cancer Test does include DR-70..This is the reason the PDX Angel Investors were interested in the purchase of these tests from PLS and Radient..Two years later Provista added to their Biomarkers with ASU.

Provista Life Sciences LLC Provides Independent Validation of Radient Pharmaceuticals' Onko-Sure(TM) Cancer Test

5/4/2010

Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today diagnostics development and commercialization firm Provista Life Sciences LLC (PLS) has independently validated Radient Pharmaceuticals' Onko-Sure in vitro diagnostic (IVD) cancer test as a potential screening tool for breast cancer detection.

RPC's Onko-Sure product validation follows PLS' completion of a phase I, 37 subject trial to provide a preliminary evaluation of the use of Radient's Onko-Sure test as a complement to Provista's existing BT Test breast cancer screen. The Phase I trial was run by Provista in the company's Arizona-based CLIA laboratory.

"We are extremely pleased with the initial results," said William Gartner, President and CEO of Provista. "We are dedicated to improving women's health and the early detection of breast cancer and RPC's Onko-Sure IVD cancer test may help our BT Test achieve even higher levels of accuracy, particularly for women over 50 where Onko-Sure showed strong differentiation between women with breast cancer versus controls."

http://www.biospace.com/News/provista-life-sciences-llc-provides-independent/179261




Next came this PR on October 14, 2010 when Radient Pharmaceuticals And Provista Life Sciences Announce New Blood Test For Lung Cancer

Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.

The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista's efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S. by the end of the fourth quarter 2010 through its standard clinical channels that include physicians, medical clinics and hospitals. The company expects to seek FDA registration for LC Sentinel™ in 2011.

According to Provista CEO William Gartner, "We are exceptionally pleased at the test results and will aggressively market and commercialize this important and potentially life-saving lung cancer test beginning in the fourth quarter 2010." Gartner also expressed high praise for the quality of the RPC's manufacturing facilities and chemicals indicating the Company is pleased to be an exclusive partner of RPC in the development of the test. In conjunction with today's announcement, RPC and Provista also announced the two Companies will execute an exclusive lab partnership agreement where Provista Life Sciences will purchase RPC reagents exclusively for the development of LC Sentinel™.

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

Next came the 5 year exclusive LPA. Here is that PR from November 2, 2010 concerning the agreement.

Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC - News) announced today it has entered into an exclusive 5-year Laboratory Services Agreement (LSA) with Provista Diagnostics Inc. (Provista). Provista conducts diagnostic research and provides CLIA laboratory developed tests and services to the general public.Under the terms of the LSA, Provista will have the exclusive rights in the U.S. to develop and market CLIA laboratory developed tests (LDTs) for cancer screening purposes using RPC's proprietary polyclonal antibodies for fibrin and fibrinogen degradation products (FDP).According to Douglas MacLellan, Executive Chairman and CEO of Radient Pharmaceuticals, "Collaboration with Provista is a natural fit for us. They have a strong, long-standing reputation for providing state-of-the-art CLIA testing services. In forging this relationship, Radient will be securing a new laboratory services and testing distribution channel for its products and we are extremely excited to expand a relationship between our two firms."The LSA provides for both minimum quarterly antibody purchases from RPC and for RPC to share in the net proceeds from the sale of any LDTs that are developed by Provista from RPC's proprietary FDP antibodies.Provista CEO William Gartner commented, "We have already successfully brought one cancer screening test to the market called the BT Test, which is a highly accurate blood test for the detection of breast cancer in women. Under our agreement with RPC we will actively pursue the development of new cancer screening and detection assays using RPC's proprietary FDP antibodies." According to Gartner this also includes accelerating the market introduction of a very sensitive FDP-derived CLIA laboratory developed test for lung cancer screening.RPC also offers its Onko-Sure® test kit; a simple non-invasive patent-pending and FDA approved in vitro diagnostic (IVD) test kit for colon-rectal cancer (CRC) recurrence monitoring. The test enables physicians and healthcare professionals to effectively monitor CRC by measuring the accumulation of FDP in the blood. FDP levels rise dramatically with the progression of this cancer.

http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm


The 2010 LOI for a reverse merger between Provista Diagnostics and radient was introduced before the Breast and Lung Cancer tests were presented.


Radient Pharmaceuticals to Acquire Provista Diagnostics Inc.
Tue, 07/13/2010

Radient Pharmaceuticals Corporation (RPC) announced today that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc. (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines. Radient Pharmaceuticals intends to acquire PDI, in a stock-for-stock transaction, when respective due diligence for both companies is successfully completed. The rationale for the merger is that PDI has all rights, patents and trademarks for diagnostic technologies that Radient Pharmaceuticals believes will strengthen and complement its core business. Pursuant to the LOI, Provista will become a wholly-owned subsidiary of Radient Pharmaceuticals.

The closing of the transaction is subject to customary closing conditions, including Radient Pharmaceuticals' shareholder approval and securing satisfactory legal and operational due diligence by both companies. Radient Pharmaceuticals and Provista Diagnostics have sixty days to complete due diligence and agree to close the merger within the following ninety days, unless both parties mutually agree to extend the closing date for the purposes of receiving required shareholder approval. If the conditions to be satisfied are not fully met in a timely fashion, the merger contemplated by the LOI may not occur.

Provista Diagnostics Inc. is a healthcare and biotechnology development company located in Phoenix, Arizona, that provides innovative tests for early disease detection to medical professionals and patients. The Company's product portfolio includes:

"The goal of this proposed merger is to build a more identifiable, broader and more profitable IVD testing business. The proposed merger represents a unique and high-value opportunity to expand CLIA testing services, test kit commercialization and research & development efforts for both RPC and PDI," said Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "PDI has established itself in the area of cancer diagnostics and CLIA laboratory testing, and the company's scientific leadership and expertise represents a strong strategic fit with RPC's existing organization. We look forward to aggressively advancing product commercialization, specifically as it relates to RPC's Onko-Sure IVD cancer test in partnership with PDI."

"We are pleased at the prospect of joining and look forward to partnering with RPC to deliver on the promise of potentially life-saving cancer testing services and products to the medical and healthcare industry," said William Gartner, President and CEO of PDI. "Furthermore, we believe our combined knowledge, experience and product portfolio will offer significant market value."

http://www.pharmpro.com/news/2010/07/radient-pharmaceuticals-acquire-provista-diagnostics-inc

In Part Three of the "Radient Reorganization Through A Reverse Merger" with Provista Diagnostics we will present more facts on our Hypothesis that will prove how Provista Diagnostics and Global Cancer Diagnostics, and Radient/AMDL Diagnostics have been quietly working behind the scenes and how they will take Provista Diagnostics public by a reverse merger with Radient.

Preview...

The lung cancer blood test still is in clinical trials, but Gartner hopes the new company will help the breast cancer blood test penetrate the commercial market.

http://www.azbio.org/provista-to-go-public-with-breast-lung-cancer-testing-technology